ReviewClinical kidney journal2022
Anaplastic lymphoma kinase inhibitors and their effect on the kidney.
Review in Clinical kidney journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Overview of pseudo-acute kidney injury.Renal failure · 2026Review
- Nephrotoxicity of immunotherapy and targeted therapies used to treat paediatric cancer.Pediatric nephrology (Berlin, Germany) · 2026Review
- Acute kidney injury: pathogenesis and therapeutic interventions.Molecular biomedicine · 2025Review
- Late-Onset Crizotinib-Associated Renal Cysts With Subsequent Regression Following Dose Reduction: A Case Report.Thoracic cancer · 2025Article
- Safety and Effectiveness of Brigatinib in Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non-Small Cell Lung Cancer (NSCLC) in Argentina: A Post-Marketing Surveillance Study.Drugs - real world outcomes · 2025Article
- Ten tips for an onco-nephrology clinic.Clinical kidney journal · 2025Review
- Nephrotoxicity of targeted therapy used to treat lung cancer.Frontiers in immunology · 2024Review
- Pseudo-AKI associated with targeted anti-cancer agents-the truth is in the eye of the filtration marker.Clinical kidney journal · 2023Article
- Targeted Cancer Therapies Causing Elevations in Serum Creatinine Through Tubular Secretion Inhibition: A Case Report and Review of the Literature.Canadian journal of kidney health and disease · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the leading cause of cancer-related mortality and approximately 5% of non-small-cell lung cancer (NSCLC) patients are positive for anaplastic lymphoma kinase (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.